Fresenius stock completes mAbxience takeover for up to EUR 750 million

Published on 10/07/2026 at 13:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Fresenius stock completed the mAbxience takeover for up to EUR 750 million on September 30, 2026. Q2 core net income rose 14 percent to EUR 470 million.

Fresenius SE – Fotorealistisch: Modernes Krankenhauszimmer mit Patientenmonitor bei Tageslicht — Fresenius SE & Co. KGaA (ISIN DE0005785604) ist ein internationaler Gesundheitskonzern mit Sitz in Bad Homburg. Das Unternehmen betreibt Krankenhäuser und entwickelt Arzneimittel und Infusionslösungen. Dieses Bild zeigt: Modernes Krankenhauszimmer mit Patientenmonitor bei Tageslicht, Illustration mit AI erstellt.

Fresenius stock was last at EUR 43.64 on Xetra on October 2, 2026, down 0.38 percent from the prior close of EUR 43.80. The healthcare group had completed the acquisition of the remaining 45 percent of mAbxience for up to EUR 750 million on September 30, 2026, according to Fresenius.

Full ownership expands Biopharma

The transaction gives Fresenius Kabi full ownership of the biosimilars platform and control over investment, manufacturing capacity and strategic decisions. The consideration includes EUR 50 million payable after site approvals, while the company said the deal was funded from available liquidity and operating cash flow.

Fresenius had acquired a 55 percent majority stake in mAbxience in August 2022 and has consolidated the business since then. The company said the acquisition should be immediately accretive to Group core earnings per share, while its full-year 2026 guidance and 2030 Biopharma ambition remain unchanged.

Q2 earnings show operating progress

In Q2/2026, group revenue rose 6 percent to EUR 5,864 million from EUR 5,571 million in Q2/2025, while group EBIT increased 10 percent to EUR 719 million from EUR 654 million. These figures are before special items, with growth stated on a constant-currency basis where applicable, according to Fresenius.

Core net income increased 14 percent to EUR 470 million from EUR 412 million, and core EPS rose 14 percent to EUR 0.83 from EUR 0.73. The comparison matters because Fresenius is pairing the mAbxience expansion with stronger reported earnings rather than relying on the acquisition alone.

Analysts see further valuation room

The published consensus was Strong Buy among 14 analysts, with 13 Buy ratings, one Hold and no Sell ratings. The average target stood at EUR 55.59, while the source reported a target range of EUR 50 to EUR 64, according to Investing.com. The average target lies 27.4 percent above the EUR 43.64 Xetra price.

Jefferies maintained a Buy rating and a EUR 55 price target on October 1, 2026, according to Finanzen.at. The next scheduled Fresenius reporting event is the Q3 2026 conference call on November 4, 2026, according to Fresenius.

Stock trades below analyst target

Fresenius stock was last at EUR 43.64 on Xetra on October 2, 2026, with a session range of EUR 43.32 to EUR 43.96 and volume of 972,865 shares. The market capitalization was EUR 24.6 billion on the same date.